Lipoxin and lipoxin analogue mediated neuroprotection and treatments
Methods and compositions for inhibiting or preventing neurodegeneration, specifically hippocampal, cortical, and/or retinal ganglion cell neurons (RGC), and degeneration and/or cell loss or treating related disorders and diseases comprising administering to a subject an effective amount of one or more lipoxin compounds and/or lipoxin analogues such that degeneration and/or cell loss of neurons is inhibited or prevented.
1. A method for providing neuroprotection from and/or treating a chronic neurodegenerative retinal or brain disorder or condition comprising administering to a subject afflicted with said disorder or condition an effective amount of lipoxin B 4 (LXB4) and/or an analog thereof, wherein the chronic retinal or brain neurodegenerative disorder or condition is selected from the group consisting of glaucoma, retinal ischemia, diabetic retinopathy, diabetic macular edema, age related macular degeneration, retinitis pigmentosa, Alzheimer's disease, multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis.
2. The method of claim 1 , wherein the chronic neurodegenerative retinal or brain disorder or condition comprises central nervous system neurodegeneration and/or neural cell loss and the effective amount of the LXB 4 and/or an analog thereof is administered to the subject in need thereof such that the neurodegeneration and/or neural cell loss is inhibited or prevented.
3. The method of claim 1 , wherein the chronic neurodegenerative retinal or brain disorder or condition comprises hippocampal neuron, cortical neuron, optic neuron or retinal ganglion cell neurodegeneration and/or cell loss.
4. The method of claim 1 , wherein the chronic neurodegenerative retinal or brain disorder or condition comprises vision loss, reduced vision, or a chronic neurodegenerative retinal or brain disorder.
5. The method of claim 1 , wherein the chronic neurodegenerative retinal or brain disorder or condition comprises vision loss or reduced vision.
6. The method of claim 1 , wherein the LXB 4 and/or an analog thereof is administered by parenteral, intravenous, subcutaneous, intramuscular, intraorbital, ophthalmic, intraocular, intravitreal, intracameral, subtenon, subconjunctival, intraperitoneal, aerosol or oral administration.
7. The method of claim 1 , wherein the LXB 4 and/or an analog thereof is administered to an eye.
8. The method of claim 7 , wherein the LXB 4 and/or an analog thereof is administered topically to the eye.
9. The method of claim 1 , wherein the concentration of the LXB 4 and/or an analog thereof is at least 0.2 nM or 50 nM.
10. The method of claim 1 , wherein the concentration of the LXB 4 and/or an analog thereof is less than 1 mM.
11. The method of claim 1 , wherein the LXB 4 and/or an analog thereof is administered in a composition.
12. The method of claim 1 , wherein the LXB 4 analog is LXB 4 methyl ester.
13. The method of claim 1 , wherein the LXB 4 analog is 15-epi-LXB 4 .
14. The method of claim 1 , wherein the LXB 4 analog is benzo-LXB 4 .
15. The method of claim 1 , wherein the glaucoma is or comprises primary open angle glaucoma, secondary open angle glaucoma or normal tension glaucoma.
16. The method of claim 7 , wherein the LXB 4 and/or analog thereof is administered to the eye by a sustained delivery device, topical gel or ointment, polymer, or intraocular gel, or sustained delivery device implant, polymer, or nanoparticles.
17. The method of claim 16 , wherein the sustained delivery device is a contact lens.